What hormone receptor status should be assessed in breast cancer biopsy specimens?

• A. ER and PR
• B. HER2 and CA-125
• C. Estrogen and Testosterone
• D. Progesterone and Androgen

Answer: (A)

In assessing breast cancer biopsy specimens, the evaluation of hormone receptor status is crucial for determining the most appropriate treatment strategy. The primary hormone receptors of interest in breast cancer are estrogen receptors (ER) and progesterone receptors (PR).

When a tumor tests positive for estrogen receptors, it indicates that the cancer cells grow in response to estrogen. Similarly, the presence of progesterone receptors suggests that the cancer is influenced by progesterone. This information is essential because it helps guide treatment decisions, such as the use of hormone therapies like tamoxifen or aromatase inhibitors, which can effectively target and inhibit hormone-dependent cancer growth.

In contrast, referencing HER2 and CA-125 does not relate to hormone receptor status. HER2 is a protein that can indicate overexpression and is linked to a more aggressive cancer type, while CA-125 is a tumor marker typically used for ovarian cancer rather than breast cancer evaluation. Furthermore, assessing estrogen and testosterone or progesterone and androgen receptors is not standard in breast cancer management, as androgen receptors are not routinely tested in this context.

Thus, the focus on ER and PR in breast cancer biopsy specimens provides vital information for customizing patient treatment and improving outcomes.